Publication Year: 2016
-
Creating molecular diagnostic tests with supervised learning using time-to-event data
-
Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC
-
Evaluation of Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer
-
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
-
Blood-based Genomic and Proteomic Testing for Newly Diagnosed Lung Cancer Patients to Facilitate Rapid Treatment Decisions and Prognostic Conversations
-
Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung
-
Blood-Based Mutation Testing in Non-small Cell Lung Carcinoma Patients Supports Individualized and Optimal Treatment
-
Shortening time from diagnosis to treatment in NSCLC: are blood-based biopsies the answer?
-
Evaluation of VeriStrat, a serum proteomic test, in the randomized, open‐label, Phase 3 LUX‐Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second‐line treatment of advanced squamous cell carcinoma (SCC) of the lung
-
Generation of high quality MALDI-TOF serum mass spectra to detect hepatocellular carcinoma in high-risk patients